Samsung Biologics vs Wacker Biotech: CDMO Comparison
Side-by-side comparison of Samsung Biologics and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Wacker Biotech holds 13 active EMA GMP certificates; Samsung Biologics does not appear in EudraGMDP.
- Composite Signal Score: Wacker Biotech 82/100 vs Samsung Biologics 68/100 — a 13-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Samsung Biologics and Wacker Biotech qualify as mRNA/LNP manufacturers; Wacker Biotech carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Samsung Biologics and Wacker Biotech qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Samsung Biologics vs Wacker Biotech
How do Samsung Biologics and Wacker Biotech compare on European GMP coverage?
Samsung Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — Samsung Biologics or Wacker Biotech?
Both Samsung Biologics and Wacker Biotech are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Samsung Biologics carries a Signal Score of 68/100 and Wacker Biotech carries 82/100 — a meaningful lead for Wacker Biotech. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →